Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Institute for Digestive Medicine details research in cancer gene therapy
October 7th, 2008
A report, 'AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer,' is newly published data in Molecular Cancer Therapeutics. "This study tried to evaluate the application of a novel cancer gene therapy using recombinant adeno-associated virus (AAV) carrying the kringle 1 domain of human hepatocyte growth factor (AAV-HGFK1) in combination with recombinant adenovirus carrying p53 gene (Ad-p53). BALB/c and nude mice models of colon cancer were established and the mice were treated with AAV-HGFK1 alone or in combination with Ad-p53," researchers in Taiwan report. "Combination of AAV-HGFK1 and Ad-p53 significantly prolonged the survival of...
Source: Cancer Weekly (2008-10-07)
|
